Literature DB >> 21470539

What is BPS and how should it be managed in real life clinical practice?

J Curtis Nickel1.   

Abstract

Entities:  

Year:  2011        PMID： 21470539      PMCID： PMC3104427          DOI： 10.5489/cuaj.11041

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  5 in total

1.  Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis.

Authors:  J Curtis Nickel; Jack Barkin; John Forrest; Phillip G Mosbaugh; J Hernandez-Graulau; David Kaufman; Keith Lloyd; Robert J Evans; C Lowell Parsons; Linda E Atkinson
Journal:  Urology       Date:  2005-04       Impact factor: 2.649

2.  Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome.

Authors:  Ali A Al-Zahrani; Jerzy B Gajewski
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

3.  Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management.

Authors:  J Curtis Nickel; Daniel Shoskes; Karen Irvine-Bird
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

Review 4.  Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal.

Authors:  Joop P van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul Irwin; Svend Mortensen; Arndt van Ophoven; John L Osborne; Ralph Peeker; Benedikte Richter; Claus Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2007-09-20       Impact factor: 20.096

5.  Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes.

Authors:  D A Shoskes; J C Nickel; R R Rackley; M A Pontari
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-07-22       Impact factor: 5.554
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.